ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin ( Sold as YONDELIS ® by Janssen, a Johnson & Johnson Company ) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study .

• Un Ciclo de IMX-110 Produjo una Supervivencia del 75 % Frente al 0 % de Supervivencia de Trabectedin ( Vendido Como YONDELIS ® Por Janssen, a Johnson & Johnson Company, un Fármaco Aprobado Por la FDA de EE. UU. ) .

• 
• One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) .
• In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs .
• IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030 .